Ron Renaud, Kailera Therapeutics CEO
Ron Renaud's new obesity biotech, Kailera, has $400M to go straight to Phase 3
There’s major money behind efforts to speed the next significant obesity company to the market.
First, it was Metsera, which launched in April with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
